August 2, 2021

Eisai’s Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures

TOKYO, Aug 2, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa…

March 26, 2021

Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021

TOKYO, Mar 26, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel (brand name: FYCOMPA,…

November 30, 2020

Eisai to Present Latest Data on Perampanel at the 74th American Epilepsy Society Annual Meeting

TOKYO, Nov 30, 2020 – (JCN Newswire) – Eisai Co., Ltd. announced today that the company will present the latest data on its in-house discovered…

November 16, 2020

Eisai Receives Approval for Indication Expansion of Anti-Epileptic Agent Fycompa for Use in Pediatric Patients

TOKYO, Nov 16, 2020 – (JCN Newswire) – Eisai Co., Ltd. announced that it has been received approval from the European Commission for the use…

October 16, 2020

Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures

TOKYO, Oct 16, 2020 – (JCN Newswire) – Eisai Co., Ltd. announced today that the supplementary new drug applications for its in-house discovered and developed…